Bridging preclinical and clinical development: Biomarker validation and qualification

Dose Optimization in Drug Development

Volumn , Issue , 2006, Pages 35-44

  Wagner, John A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 53849123387     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (19)

1. Blue JW, Colburn WA. Efficacy measures: surrogates or clinical outcomes. J Clin Pharmacol 1996; 36:767-770.
2. Rolan P. The contribution of clinical pharmacology surrogates and models to drug development: a critical appraisal. Br J Clin Pharmacol 1997; 44:219-225.
3. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints:preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69:89.
4. Lesko LJ, Atkinson AJ. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 2001; 41:347-366.
5. Reichert JM. Trends in development and approval times for new therapeutics in the United States. Nat Rev Drug Discov 2003; 2:695.
6. DiMasi JA. The value of improving the productivity of the drug development process:faster times and better decisions. Pharmacoeconomics 20(suppl 3):1.
7. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econom 2003; 22:151.
8. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003; 2:566.
9. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3:711.
10. Innovation or stagnation? Challenge and opportunity on the critical path to new medical products. United States Food and Drug Administration, 2004.
11. Lee JW, Devanarayan V, Barrett YC, et al. Fit-for-purpose method development and validation for successful biomarker measurment. Pharmaceutical Res 2006; [Epub ahead of print].
12. Zerhouni E. Medicine. The NIH roadmap. Science 2003; 302:63-72. http:// nihroadmap.nih.gov.
13. Wagner JA. Overview of biomarkers and surrogate endpoints in drug development. Disease Markers 2002; 18:41-46.
14. Mildvan D, Landay A, De Gruttola V, Machado SG, Kagan J. An approach to the validation of markers for use in AIDS clinical trials. Clin Infect Dis 1997; 24:764-774.
15. Exposure-Response Relationships-Study Design, Data Analysis, and Regulatory Applications. Guidance for Industry, 2003.
16. Sullivan Pepe M, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001; 93:1054-1061.
17. Bjornsson TD. Biomarkers: applications in drug development. Eur Pharmaceut Rev 2005; 1:17-21.
18. Echt DS, Liebon PR, Mitchell B, Peters RW, Obias-Manno D. Mortality and morbidity of patients receiving encainide, flecainide or placebo: the cardiac arrhythmia suppression trial. N Engl J Med 1991; 324:781-788.
19. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.